Institut National De La Sante Et De La Recherche Medicale

Centre Leon Berard

Owkin, Inc.

Owkin France Sas

Centre National De La Recherche Scientifique

Université´ D'aix-Marseille

Universite Claude Bernard – Lyon1

Hospices Civils De Lyon

Université Claude Bernard

Centre Leon Bernard

Jean-Yves Blay

Pierre Courtiol

Gilles Wainrib

Charles Maussion

Thomas Clozel

Franck Galland

Virginie Millet

Caroline Giessner

Françoise Galateau Salle

Laurent Alberti

Françoise Galateau Sallé

Philippe Naquet

A method and apparatus of a device that classifies a mesothelioma image is described. In an exemplary embodiment, the device segments the mesothelioma image into a region of interest that includes information useful for classification, and a background region, by applying a first convolutional neural network. In addition, the device tiles the region of interest into a set of tiles. For each tile, the device extracts a feature vector of that tile by applying a second convolutional neural network, where the features of the feature vectors represent local descriptors of the tile. Furthermore, the device processes the extracted feature vectors of the set of tiles to classify the image.

Systems and methods for mesothelioma feature detection and enhanced prognosis or response to treatment

Sarcomas are rare malignant tumors arising from the mesenchymal tissues at all body sites. The inventors show that in a mouse model of p16/p19 deficiency prone to tumor development, the absence of the mouse pantetheinase Vnn1 enhances the frequency of aggressive fibrosarcomas. They also show that reintroduction of a catalytically active form of the Vnn1 pantetheinase limits tumor growth in vivo. Interestingly, VNN1 expression in human sarcomas is associated with reduced aggressiveness and lower risk of metastatic relapse in patients. In conclusion, Vnn1 represents a novel marker of sarcoma and may modulate tumor aggressiveness by sustaining myofibroblast cell differentiation, thereby limiting evolution towards undifferentiated tumors. The present invention relates to the use of Vnn1 as a biomarker and a therapeutic target in sarcomas.

Use of VNN1 as a biomarker and a therapeutic target in sarcomas

The subject of the present invention concerns proteins with IL-6 inhibiting activity and thier use, and the use of proteins containing at least the amino acid seqeunce SEQ ID NO. 4 as medicianl product, in paritcular as anti-cancerous agent.

Proteins with IL-6 inhibiting activity

Growing community of inventors

Lyons, France

Jean-Yves Blay